EE05761B1 - Kombineeritud ravimkoostis diabeedi ning ainevahetushäirete raviks - Google Patents

Kombineeritud ravimkoostis diabeedi ning ainevahetushäirete raviks

Info

Publication number
EE05761B1
EE05761B1 EEP201300007A EEP201300007A EE05761B1 EE 05761 B1 EE05761 B1 EE 05761B1 EE P201300007 A EEP201300007 A EE P201300007A EE P201300007 A EEP201300007 A EE P201300007A EE 05761 B1 EE05761 B1 EE 05761B1
Authority
EE
Estonia
Prior art keywords
pharmaceutical composition
diabetes
metabolic disorders
treatment
combined pharmaceutical
Prior art date
Application number
EEP201300007A
Other languages
English (en)
Inventor
Olegiliich Epshtein
Original Assignee
Olegiliich Epshtein
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44899155&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE05761(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from RU2010130348/15A external-priority patent/RU2531048C2/ru
Priority claimed from RU2011127051/15A external-priority patent/RU2509572C2/ru
Application filed by Olegiliich Epshtein filed Critical Olegiliich Epshtein
Publication of EE201300007A publication Critical patent/EE201300007A/et
Publication of EE05761B1 publication Critical patent/EE05761B1/et

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Käesolev leiutis esitab ravimikoostise manustamiseks patsiendile, kes kannatab diabeedi ja muude ainevahetushäirete all, ravimikoostis sisaldab a) inimese insuliiniretseptori vastase antikeha aktiveeritud ja potentseeritud vormi ning b) endoteliaalse NO süntaasi vastase antikeha aktiveeritud ja potentseeritud vormi.
EEP201300007A 2010-07-21 2011-07-15 Kombineeritud ravimkoostis diabeedi ning ainevahetushäirete raviks EE05761B1 (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
RU2010130348/15A RU2531048C2 (ru) 2010-07-21 2010-07-21 Лекарственное средство для уменьшения резистентности к инсулину и лечения сахарного диабета и способ повышения эффективности лечения сахарного диабета инсулином и/или гипогликемическими препаратами
RU2011127051/15A RU2509572C2 (ru) 2011-07-01 2011-07-01 Лекарственное средство для уменьшения резистентности к инсулину и для лечения сахарного диабета, способ уменьшения резистентности к инсулину, способ лечения сахарного диабета и способ лечения сахарного диабета инсулином и/или гипогликемическими препаратами
PCT/IB2011/002177 WO2012010966A2 (en) 2010-07-21 2011-07-15 A combination pharmaceutical composition and methods of treating diabetes and metabolic disorders

Publications (2)

Publication Number Publication Date
EE201300007A EE201300007A (et) 2013-08-15
EE05761B1 true EE05761B1 (et) 2016-03-15

Family

ID=44899155

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP201300007A EE05761B1 (et) 2010-07-21 2011-07-15 Kombineeritud ravimkoostis diabeedi ning ainevahetushäirete raviks

Country Status (30)

Country Link
US (1) US8617555B2 (et)
EP (2) EP3693018A1 (et)
JP (2) JP2013533268A (et)
KR (2) KR20130103486A (et)
CN (1) CN103118707A (et)
AR (1) AR082312A1 (et)
AU (1) AU2011281240B2 (et)
BR (1) BR112013001299A2 (et)
CA (1) CA2805961A1 (et)
CL (1) CL2013000200A1 (et)
CZ (1) CZ2013124A3 (et)
DE (1) DE112011102396T5 (et)
DK (1) DK201370089A (et)
EA (1) EA029847B1 (et)
EE (1) EE05761B1 (et)
ES (1) ES2445846R1 (et)
FI (1) FI20135152L (et)
FR (1) FR2962913A1 (et)
GB (2) GB2552405B (et)
IT (1) ITTO20110627A1 (et)
LT (1) LT5980B (et)
MX (1) MX2013000804A (et)
MY (1) MY160979A (et)
NO (1) NO20130265A1 (et)
NZ (1) NZ606964A (et)
PE (1) PE20130815A1 (et)
PH (1) PH12013500140A1 (et)
SE (1) SE1350212A1 (et)
SG (1) SG187578A1 (et)
WO (1) WO2012010966A2 (et)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2181297C2 (ru) 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
UA76638C2 (en) 2002-08-02 2006-08-15 Oleh Illich Epshtein Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon
RU2309732C1 (ru) * 2006-03-13 2007-11-10 Олег Ильич Эпштейн Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата
EA200802440A1 (ru) * 2006-06-06 2009-06-30 Олег Ильич ЭПШТЕЙН Лекарственное средство для лечения ожирения, сахарного диабета и заболеваний с нарушением толерантности к глюкозе
US8637034B2 (en) 2010-07-15 2014-01-28 Oleg I. Epshtein Pharmaceutical compositions comprising activated-potentiated antibodies to interferon-gamma and S100 protein
EA030566B1 (ru) * 2010-07-15 2018-08-31 Олег Ильич ЭПШТЕЙН Способ повышения терапевтической эффективности активированной-потенцированной формы антитела к эндогенной биомолекуле и фармацевтическая композиция
ITTO20110641A1 (it) 2010-07-15 2012-01-16 Oleg Iliich Epshtein Composizioni farmaceutiche e metodi di trattamento
CA2805963A1 (en) 2010-07-21 2012-01-26 Oleg Iliich Epshtein A method of treating attention deficit hyperactivity disorder
KR20130102542A (ko) * 2010-07-21 2013-09-17 올레그 일리치 엡쉬테인 현기증, 동요병 및 증식형-혈관 이긴장증 치료용 제약학적 복합 조성물 및 치료 방법들
PH12013500142A1 (en) 2010-07-21 2013-03-11 Oleg Iliich Epshtein Combination pharmaceutical composition and methods of treating diseases or conditions associated with respiratory disease or condition
WO2012017328A2 (en) * 2010-08-06 2012-02-09 Oleg Iliich Epshtein Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
TWI588153B (zh) * 2012-05-18 2017-06-21 中國醫藥大學 多胜肽、編碼該多胜肽之核酸分子、以及該多胜肽之應用
RU2013111961A (ru) 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем
RU2013111962A (ru) 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4311897A (en) 1979-08-28 1982-01-19 Union Carbide Corporation Plasma arc torch and nozzle assembly
US5811437A (en) * 1996-05-21 1998-09-22 Eli Lilly And Company Methods of increasing nitric oxide synthesis
US6150500A (en) * 1996-07-12 2000-11-21 Salerno; John C. Activators of endothelial nitric oxide synthase
WO1999026657A1 (en) * 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibitors of nitric oxide synthase
US6933272B1 (en) * 1998-09-22 2005-08-23 Erik Helmerhorst Use of non-peptidyl compounds for the treatment of insulin related ailments
RU2181297C2 (ru) * 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
UA76641C2 (uk) 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування захворювань передміхурової залози
UA76638C2 (en) 2002-08-02 2006-08-15 Oleh Illich Epshtein Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon
UA76639C2 (uk) * 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування еректильних дисфункцій
JP2006501224A (ja) * 2002-08-22 2006-01-12 ニュートリション ２１、インコーポレイテッド アルギニンケイ酸塩イノシトール複合体およびその使用
CA2518965C (en) 2003-03-14 2018-10-30 Nutrition Research Inc. Homeopathic formulations useful for treating pain and/or inflammmation
KR20060125849A (ko) * 2004-01-20 2006-12-06 아스텔라스세이야쿠 가부시키가이샤 발기부전 치료 방법
EA200802440A1 (ru) * 2006-06-06 2009-06-30 Олег Ильич ЭПШТЕЙН Лекарственное средство для лечения ожирения, сахарного диабета и заболеваний с нарушением толерантности к глюкозе
RU2438707C2 (ru) * 2006-06-06 2012-01-10 Олег Ильич Эпштейн Лекарственное средство для перорального лечения сахарного диабета и других заболеваний, сопровождающихся нарушением толерантности к глюкозе, и способ получения твердой лекарственной формы для пероральной терапии сахарного диабета и других заболеваний, сопровождающихся нарушением толерантности к глюкозе
GB0812019D0 (en) * 2008-07-02 2008-08-06 Asterion Ltd Insulin
EA030566B1 (ru) * 2010-07-15 2018-08-31 Олег Ильич ЭПШТЕЙН Способ повышения терапевтической эффективности активированной-потенцированной формы антитела к эндогенной биомолекуле и фармацевтическая композиция
ITTO20110641A1 (it) * 2010-07-15 2012-01-16 Oleg Iliich Epshtein Composizioni farmaceutiche e metodi di trattamento
US8637034B2 (en) * 2010-07-15 2014-01-28 Oleg I. Epshtein Pharmaceutical compositions comprising activated-potentiated antibodies to interferon-gamma and S100 protein
PH12013500142A1 (en) * 2010-07-21 2013-03-11 Oleg Iliich Epshtein Combination pharmaceutical composition and methods of treating diseases or conditions associated with respiratory disease or condition
KR20130102542A (ko) * 2010-07-21 2013-09-17 올레그 일리치 엡쉬테인 현기증, 동요병 및 증식형-혈관 이긴장증 치료용 제약학적 복합 조성물 및 치료 방법들

Also Published As

Publication number Publication date
ITTO20110627A1 (it) 2012-01-22
ES2445846A2 (es) 2014-03-05
BR112013001299A2 (pt) 2017-11-21
US20130064824A1 (en) 2013-03-14
JP2016222684A (ja) 2016-12-28
CZ2013124A3 (cs) 2013-06-12
MY160979A (en) 2017-03-31
WO2012010966A3 (en) 2012-03-29
EP2595658A2 (en) 2013-05-29
KR20180127515A (ko) 2018-11-28
GB2496799B (en) 2017-11-22
JP2013533268A (ja) 2013-08-22
GB2496799A (en) 2013-05-22
KR20130103486A (ko) 2013-09-23
GB201302924D0 (en) 2013-04-03
AR082312A1 (es) 2012-11-28
GB2552405A (en) 2018-01-24
GB201707872D0 (en) 2017-06-28
FI20135152A7 (fi) 2013-02-21
CL2013000200A1 (es) 2015-01-23
EA201300124A1 (ru) 2013-12-30
SE1350212A1 (sv) 2013-04-22
EA029847B1 (ru) 2018-05-31
US8617555B2 (en) 2013-12-31
AU2011281240B2 (en) 2016-07-07
PH12013500140A1 (en) 2013-03-11
DE112011102396T5 (de) 2013-05-02
DK201370089A (en) 2013-02-19
LT5980B (lt) 2013-12-27
GB2552405B (en) 2018-05-30
MX2013000804A (es) 2013-10-28
NO20130265A1 (no) 2013-04-18
PE20130815A1 (es) 2013-07-18
FR2962913A1 (fr) 2012-01-27
LT2013018A (lt) 2013-10-25
ES2445846R1 (es) 2015-01-02
AU2011281240A1 (en) 2013-03-07
SG187578A1 (en) 2013-03-28
EE201300007A (et) 2013-08-15
NZ606964A (en) 2015-08-28
EP3693018A1 (en) 2020-08-12
FI20135152L (fi) 2013-02-21
WO2012010966A2 (en) 2012-01-26
CA2805961A1 (en) 2012-01-26
CN103118707A (zh) 2013-05-22

Similar Documents

Publication Publication Date Title
FI20135152A7 (fi) Farmaseuttinen yhdistelmäkoostumus ja menetelmiä diabeteksen ja metabolisten sairauksien hoidossa
EA201401028A1 (ru) Фармацевтическая композиция, содержащая эмпаглифлозин и лекарственное средство от ожирения
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
EA201170669A1 (ru) Лечение пирфенидоном пациентов с атипичной функцией печени
UA103915C2 (ru) Твердая лекарственная форма, которая содержит линаглиптин и ингибитор sglt2, и ее применение
EA201291336A1 (ru) Замещенные 5-фтор-1н-пиразолопиридины и их применение
EA201590655A1 (ru) Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений
EA201290171A1 (ru) Вводимые перорально кортикостероидные композиции
EA201490521A1 (ru) Варианты фактора роста фибробластов 21
MX347893B (es) Conjugados de farmaco y anticuerpo humano contra factor de tejido.
MX2012007806A (es) Composiciones farmaceuticas para administracion oral de peptidos de insulina.
TW201129382A (en) Antibody formulation and therapeutic regimens
UA109991C2 (xx) Карбаматні сполуки, їх отримання і застосування
NZ707139A (en) Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level
FI20135146A7 (fi) Farmaseuttiset koostumukset ja hoitomenetelmät
CY1112320T1 (el) Τιτλοδοτηση της ταπενταδολης
BR112012007888A2 (pt) "métodos de tratamento usando anticorpos anti-ldl oxidada".
UA109414C2 (uk) Арильовані камфени та фармацевтична композиція на їх основі
GB2496795A (en) A combination pharmaceutical composition and methods of treating diseases or conditions associated with the cardiovascular system
MX355015B (es) Uso de hidroxamatos de indolilo e indolinilo para tratar insuficiencia cardiaca o lesión neuronal.
UA112981C2 (uk) Варіант людського gdnf
MX2013007959A (es) Formas farmaceuticas orales de amida {2-[(1s)-1-(3-etoxi-4-metoxi- fenil]-2-metansulfonil-etil]-3-oxo-2,,3-dihidro-1h-isoindol -4-il}-del acido ciclopropancarboxilico.
EA201492045A1 (ru) Композиция для назального применения
EA200900173A1 (ru) Фармацевтическая композиция для перорального применения
EA201992775A3 (ru) Конъюгаты антител человека против тканевого фактора с лекарственными препаратами

Legal Events

Date Code Title Description
MM4A Lapsed by not paying the annual fees

Effective date: 20180715